EUPATI

As a partner in the European Patients' Academy on Therapeutic Innovation, EURORDIS is developing educational content on medicine risk/benefit assessment

EUPATIEURORDIS is a partner in the European Patients' Academy on Therapeutic Innovation (EUPATI) – an Innovative Medicines Initiative (IMI) funded consortium of 29 organisations, including patient organisations, academic institutions and European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies.

The five-year project, which launched in February 2012, develops educational material, training courses and public information to educate patients and the public about medicines development processes, increasing the capacity of patients to be effective advocates and advisors in medicines research and regulatory processes. EURORDIS is involved in the areas of content development for safety and risk/benefit assessment of novel and existing medicines as well as the organisation of specific training sessions.

Page created: 07/08/2013
Page last updated: 06/11/2014
 
 
The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseasesRare Disease International Bringing together patients, families and experts to share experiences in a moderated multi-language forum. RareConnect The Rare Barometer Programme is a EURORDIS initiative that carries out surveys to transform rare disease patients' experiences into figures and facts that can be shared with decision-makers.Rare Barometer An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases